戻る Agenda
ON DEMAND - Microbiome Therapies Beyond Fecal Microbiota Transplantation: Challenges and Opportunities
Session Chair(s)
Anita Nelsen
Executive Vice President, Translational Medicine
Parexel, United States
Live biotherapeutics, an emerging new class of drug products which leverage living microorganisms, have potential to prevent, treat or cure diseases or conditions. Leveraging next generation sequencing and other -omics technologies researchers are gaining a greater understanding of the human microbiome and the role it plays in human health, drug metabolism and disease. Experimentation with fecal transplants have shown promise in treating patients with C. difficile infection and IBD and researchers believe there are many more opportunities to significantly improve human health. This session will explore the unique challenges in developing this new class of precision medicines.
Learning Objective : Explain the microbiome and how it is being used to develop a new class of personalized medicines; Describe the unique clinical development, requlatory, manufacturing, and quality challenges faced when developing live biotherapeutics and approaches to overcome these challenges..
Speaker(s)
Microbiome Therapies Beyond Fecal Microbiota Transplantation: Solutions to Address Challenges
Anmol Grover, PHD
Halloran Consulting Group, United States
Clinical Strategy Consultant